Integra LifeSciences Holdings (IART)
Interest coverage
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 28,411 | 132,446 | 263,488 | 265,072 | 165,101 |
| Interest expense | US$ in thousands | -4,500 | 51,377 | 49,594 | 50,395 | 71,581 |
| Interest coverage | — | 2.58 | 5.31 | 5.26 | 2.31 |
December 31, 2024 calculation
Interest coverage = EBIT ÷ Interest expense
= $28,411K ÷ $-4,500K
= —
The interest coverage ratio for Integra LifeSciences Holdings has shown varying trends over the years. In December 2020, the ratio was 2.31, indicating that the company generated operating income that could cover its interest expenses 2.31 times. This level suggests a moderate ability to meet interest obligations.
By December 2021, the interest coverage ratio improved significantly to 5.26, signaling a stronger ability to cover interest payments from operating income. This increase is a positive indicator of the company's financial health and its capability to manage debt obligations.
In December 2022, the interest coverage ratio remained strong at 5.31, maintaining the company's ability to comfortably meet interest expenses with operating profits. This consistency in a healthy interest coverage ratio reflects continued financial stability and efficient debt management by Integra LifeSciences Holdings.
However, by December 2023, the interest coverage ratio declined to 2.58, indicating a slight reduction in the company's ability to cover interest payments from operating earnings. This decrease may warrant further monitoring to ensure sustainable financial performance.
Moreover, the data for December 31, 2024, is missing (indicated by “—”), making it challenging to provide a comprehensive analysis for that year. It is essential for stakeholders to obtain updated information to assess the company's financial position accurately.
Peer comparison
Dec 31, 2024